Concepedia

Divina Glah

DG

Statistics

Publications

6

Citations

156

H-Index

6

Active since

2016

Affiliations

Novo Nordisk (United Kingdom)(Current)

Novo Nordisk (Denmark)

Oxfordshire Clinical Commissioning Group

Divina Glah is an author at Novo Nordisk (United Kingdom) specializing in diabetes mellitus, basal insulin therapy, and glucagon-like peptide 1 receptor agonism.

Publications per year

2016–2021

6

Publications

6

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

Michał Witkowski, Lars Wilkinson, Neil Webb et al. · Diabetes Therapy · 2018 · 46 citations · Full text

, , +17

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting

Melanie J. Davies, Divina Glah, Barrie Chubb et al. · PharmacoEconomics · 2016 · 31 citations

, , +13

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

Matthew Capehorn, Nino Hallén, James Baker‐Knight et al. · Diabetes Therapy · 2021 · 25 citations · Full text

, , +17

Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

Barnaby Hunt, Divina Glah · Diabetes Therapy · 2017 · 19 citations · Full text

, , +17

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin

Michał Witkowski, Lars Wilkinson, Neil Webb et al. · Diabetes Therapy · 2018 · 18 citations · Full text

, , +17

1–5 of 6